Human Fas Ligand / TNFSF6 Protein, His Tag, premium grade
分子別名(Synonym)
FASLG,ALPS1B,APT1LG1,CD178,CD95L,FASL,TNFSF6
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human Fas Ligand, His Tag, premium grade (FAL-H5241) is expressed from human 293 cells (HEK293). It contains AA Pro 134 - Leu 281 (Accession # AAH17502.1).
Predicted N-terminus: His
該產(chǎn)品是在我們嚴(yán)格的質(zhì)量控制體系下生產(chǎn)的,該體系包含一套全面的測試,包括無菌和內(nèi)毒素測試。在早期臨床前階段,產(chǎn)品性能經(jīng)過仔細(xì)驗(yàn)證和測試,以確保其與細(xì)胞培養(yǎng)用途或任何其他應(yīng)用的兼容性。當(dāng)準(zhǔn)備過渡到后期臨床階段時(shí),我們還提供定制的GMP蛋白質(zhì)服務(wù),以滿足您的需求。我們將與您合作,根據(jù)您的要求定制和開發(fā)GMP級(jí)產(chǎn)品,該產(chǎn)品也符合細(xì)胞療法細(xì)胞制造中使用的原材料和輔助材料的要求。
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 18.8 kDa. The protein migrates as 25-33 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 0.1 EU per μg by the LAL method.
無菌(Sterility)
Negative
支原體(Mycoplasma)
Negative.
純度(Purity)
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
Fas ligand也稱為FasL、CD178、CD95L或TNFSF6,是一種屬于腫瘤壞死因子(TNF)家族的同源三聚體II型跨膜蛋白。其與受體的結(jié)合誘導(dǎo)細(xì)胞凋亡。Fas配體/受體相互作用在免疫系統(tǒng)的調(diào)節(jié)和癌癥的進(jìn)展中起著重要作用。成熟的人Fas配體由179個(gè)氨基酸(aa)的細(xì)胞外結(jié)構(gòu)域(ECD)、22個(gè)氨基酸的跨膜片段和80個(gè)氨基酸的細(xì)胞質(zhì)結(jié)構(gòu)域組成。在ECD中,人Fas配體分別與小鼠和大鼠Fas配體具有81%和78%的氨基酸序列同一性。Fas-Fas配體結(jié)合引發(fā)的細(xì)胞凋亡在免疫系統(tǒng)的調(diào)節(jié)中起著重要作用。其功能包括:T細(xì)胞穩(wěn)態(tài)、細(xì)胞毒性T細(xì)胞活性、免疫特權(quán)、母體耐受、腫瘤反擊。Fas介導(dǎo)的細(xì)胞凋亡缺陷可能導(dǎo)致現(xiàn)有腫瘤的發(fā)生和耐藥性。Fas的種系突變與自身免疫性淋巴增生綜合征(ALPS)有關(guān),ALPS是一種兒童期細(xì)胞凋亡疾病。
關(guān)鍵字: Fas Ligand;Fas Ligand蛋白;TNFSF6蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。